Duzallo

RSS
Withdrawn

This medicine's authorisation has been withdrawn

allopurinol / lesinurad
MedicineHumanWithdrawn
  • Application under evaluation
  • CHMP opinion
  • European Commission decision

Overview

On 31 July 2020, the European Commission withdrew the marketing authorisation for Duzallo (allopurinol / lesinurad) in the European Union (EU). The withdrawal was at the request of the marketing authorisation holder, Grunenthal GmbH, which notified the European Commission of its decision not to market the product in the EU for commercial reasons. 

Duzallo was granted marketing authorisation in the EU on 23 August 2018 for gout. The marketing authorisation was initially valid for a 5-year period. The product had not been marketed in the EU since 2018.

The European Public Assessment Report (EPAR) for Duzallo is updated to indicate that the marketing authorisation is no longer valid.

български (BG) (780.71 KB - PDF)

View

español (ES) (684.16 KB - PDF)

View

čeština (CS) (751.99 KB - PDF)

View

dansk (DA) (680.84 KB - PDF)

View

Deutsch (DE) (684.99 KB - PDF)

View

eesti keel (ET) (679.15 KB - PDF)

View

ελληνικά (EL) (790.77 KB - PDF)

View

français (FR) (685.18 KB - PDF)

View

hrvatski (HR) (698.5 KB - PDF)

View

italiano (IT) (683.73 KB - PDF)

View

latviešu valoda (LV) (737.62 KB - PDF)

View

lietuvių kalba (LT) (704.71 KB - PDF)

View

magyar (HU) (744.31 KB - PDF)

View

Malti (MT) (752.99 KB - PDF)

View

Nederlands (NL) (684.07 KB - PDF)

View

polski (PL) (751.21 KB - PDF)

View

português (PT) (683.78 KB - PDF)

View

română (RO) (703.65 KB - PDF)

View

slovenčina (SK) (751.33 KB - PDF)

View

slovenščina (SL) (744.53 KB - PDF)

View

Suomi (FI) (683.59 KB - PDF)

View

svenska (SV) (680.84 KB - PDF)

View

Product information

български (BG) (2.19 MB - PDF)

View

español (ES) (1.06 MB - PDF)

View

čeština (CS) (1.8 MB - PDF)

View

dansk (DA) (1.06 MB - PDF)

View

Deutsch (DE) (1.08 MB - PDF)

View

eesti keel (ET) (1.05 MB - PDF)

View

ελληνικά (EL) (2.19 MB - PDF)

View

français (FR) (1.08 MB - PDF)

View

hrvatski (HR) (1.05 MB - PDF)

View

íslenska (IS) (1.06 MB - PDF)

View

italiano (IT) (1.06 MB - PDF)

View

latviešu valoda (LV) (1.83 MB - PDF)

View

lietuvių kalba (LT) (310.39 KB - PDF)

View

magyar (HU) (1.8 MB - PDF)

View

Malti (MT) (1.89 MB - PDF)

View

Nederlands (NL) (2.57 MB - PDF)

View

norsk (NO) (1.05 MB - PDF)

View

polski (PL) (1.84 MB - PDF)

View

português (PT) (1.06 MB - PDF)

View

română (RO) (1.09 MB - PDF)

View

slovenčina (SK) (1.8 MB - PDF)

View

slovenščina (SL) (1.76 MB - PDF)

View

Suomi (FI) (307.79 KB - PDF)

View

svenska (SV) (1.05 MB - PDF)

View
Latest procedure affecting product information: IB/0002/G
31/07/2019
icon globe

This medicine’s product information is available in all official EU languages.
Select 'available languages' to access the language you need.

 

Product information documents contain:

  • summary of product characteristics (annex I);
  • manufacturing authorisation holder responsible for batch release (annex IIA);
  • conditions of the marketing authorisation (annex IIB);
  • labelling (annex IIIA);
  • package leaflet (annex IIIB).

български (BG) (668.21 KB - PDF)

View

español (ES) (644.06 KB - PDF)

View

čeština (CS) (660.86 KB - PDF)

View

dansk (DA) (644.95 KB - PDF)

View

Deutsch (DE) (644.9 KB - PDF)

View

eesti keel (ET) (644.55 KB - PDF)

View

ελληνικά (EL) (667.74 KB - PDF)

View

français (FR) (643.47 KB - PDF)

View

hrvatski (HR) (643.66 KB - PDF)

View

íslenska (IS) (643.5 KB - PDF)

View

italiano (IT) (643.5 KB - PDF)

View

latviešu valoda (LV) (661.54 KB - PDF)

View

lietuvių kalba (LT) (644.78 KB - PDF)

View

magyar (HU) (660.24 KB - PDF)

View

Malti (MT) (660.12 KB - PDF)

View

Nederlands (NL) (665.04 KB - PDF)

View

norsk (NO) (645.67 KB - PDF)

View

polski (PL) (660.39 KB - PDF)

View

português (PT) (644.36 KB - PDF)

View

română (RO) (644.37 KB - PDF)

View

slovenčina (SK) (660.88 KB - PDF)

View

slovenščina (SL) (659.37 KB - PDF)

View

Suomi (FI) (644.54 KB - PDF)

View

svenska (SV) (644.23 KB - PDF)

View

Product details

Name of medicine
Duzallo
Active substance
  • allopurinol
  • lesinurad
International non-proprietary name (INN) or common name
  • allopurinol
  • lesinurad
Therapeutic area (MeSH)
Gout
Anatomical therapeutic chemical (ATC) code
M04AA51

Pharmacotherapeutic group

Antigout preparations

Therapeutic indication

Duzallo is indicated in adults for the treatment of hyperuricaemia in gout patients who have not achieved target serum uric acid levels with an adequate dose of allopurinol alone.

Authorisation details

EMA product number
EMEA/H/C/004412
Marketing authorisation holder
Grunenthal GmbH

Zieglerstrasse 6
D-52078 Aachen
Germany

Opinion adopted
28/06/2019
Marketing authorisation issued
23/08/2018
Revision
2

Assessment history

This page was last updated on

Share this page